Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes

Diabetes

Volumn 57, Issue 6, 2008, Pages 1674-1682

  Goldberg, Ira J ^a   Hu, Yunying ^a   Noh, Hye Lim ^a   Wei, Justin ^a   Huggins, Lesley Ann ^a   Rackmill, Marnie G ^a   Hamai, Hiroko ^a   Reid, Brendan N ^a   Blaner, William S ^a   Huang, Li Shin ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN E; HEPARAN SULFATE; HEPARAN SULFATE N DEACETYLASE; HEPARAN SULFATE N SULFOTRANSFERASE 1; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; METHIONINE; PROTEOGLYCAN; PROTEOGLYCAN SULFATION ENZYME; STREPTOZOCIN; SULFUR 35; TYLOXAPOL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL INTAKE; COMPARATIVE STUDY; CONTROLLED STUDY; CULTURE MEDIUM; DYSLIPIDEMIA; GLUCOSE INTAKE; HETEROZYGOSITY; LIQUID CHROMATOGRAPHY; LIVER CELL CULTURE; MALE; METABOLIC CLEARANCE RATE; MOUSE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; ULTRACENTRIFUGATION; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; CROSS BREEDING; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCOSE BLOOD LEVEL; LIVER; LIVER TUMOR; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY;

ANIMALS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, DIETARY; CROSSES, GENETIC; DIABETES MELLITUS, EXPERIMENTAL; DYSLIPIDEMIAS; LIPIDS; LIPOPROTEINS; LIVER; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL; TRIGLYCERIDES; TUMOR CELLS, CULTURED;

EID: 48249099359     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-0083     Document Type: Article

References (44)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
2. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care 21:160-178, 1998
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
4. Goldberg IJ: Why does diabetes increase atherosclerosis? I don't know! J Clin Invest 114:613-615, 2004
5. Reusch JE: Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J Clin Invest 112:986-988, 2003
6. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031, 1998
7. Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, Goldberg IJ, Shachter NS: Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice J Clin Invest 105:1807-1818, 2000
8. Keren P, George J, Shaish A, Levkovitz H, Janakovic Z, Afek A, Goldberg I, Kopolovic J, Keren G, Harats D: Effect of hyperglycemia and hyperlip- idemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. Diabetes 49:1064-1069, 2000
9. Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, von Herrath MG, Chait A, Bornfeldt KE: Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 114:659-668, 2004
10. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, Ra- masamy R, Goldberg IJ: Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 115:2434-2443, 2005
11. Ginsberg HN: Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 45 Suppl 3:S27-30, 1996
12. Kako Y, Huang LS, Yang J, Katopodis T, Ramakrishnan R, Goldberg IJ: Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: effects on lipoproteins and atherosclerosis. J Lipid Res 40:21852194, 1999
13. Gaw A, Mancini FP, Ishibashi S: Rapid genotyping of low density lipopro- tein receptor knockout mice using a polymerase chain reaction technique. Lab Anim 29:447-449, 1995
14. Teupser D, Persky AD, Breslow JL: Induction of atherosclerosis by low-fat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: comparison of lesions ofthe aortic root, brachiocephalic artery, and whole aorta (en face measurement). Arterioscler Thromb Vasc Biol 23:19071913, 2003
15. Nishina PM, Naggert JK, Verstuyft J, Paigen B: Atherosclerosis in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism 43:554-558, 1994
16. Kako Y, Masse M, Huang LS, Tall AR, Goldberg IJ: Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J Lipid Res 43:872-877, 2002
17. Voyiaziakis E, Ko C, O'Rourke SM, Huang LS: Genetic control of hepatic apoB-100 secretion in human apoB transgenic mouse strains. J Lipid Res 40:2004-2012, 1999
18. Vogel S, Piantedosi R, O'Byrne SM, Kako Y, Quadro L, Gottesman ME, Goldberg IJ, Blaner WS: Retinol-binding protein-deficient mice: biochemical basis for impaired vision. Biochemistry 41:15360-15368, 2002
19. Blaner WS: Radioimmunoassays for retinol-binding protein, cellular reti- nol-binding protein, and cellular retinoic acid-binding protein. Meth Enzy- mology 189:270-281 189:270-281, 1990
20. Kunjathoor VV, Wilson DL, LeBoeuf RC: Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 97:1767-1773, 1996
21. Williams KJ, Liu ML, Zhu Y, Xu X, Davidson WR, McCue P, Sharma K: Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes 54:1116-1122, 2005
22. Goldberg IJ, Dansky HM: Diabetic vascular disease: an experimental objective. Arterioscler Thromb Vasc Biol 26:1693-1701, 2006
23. Wu KK, Wu TJ, Chin J, Mitnaul LJ, Hernandez M, Cai TQ, Ren N, Waters MG, Wright SD, Cheng K: Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 181:251-259, 2005
24. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit- Dahm KA: Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109:1536-1542, 2004
25. Reaven P, Merat S, Casanada F, Sutphin M, Palinski W: Effect of strepto- zotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb VascBiol 17:2250-2256,1997
26. Lyngdorf LG, Gregersen S, Daugherty A, Falk E: Paradoxical reduction of atherosclerosis in apoE-deficient mice with obesity-related type 2 diabetes. Cardiovasc Res 59:854-862, 2003
27. Wu L, Vikramadithyan R, Yu S, Pau C, Hu Y, Goldberg IJ, Dansky HM: Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis. J Lipid Res 47:2215-2222, 2006
28. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417:750-754, 2002
29. Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC: LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am J Physiol Endocrinol Metab 282:E207-E214, 2002
30. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamada N: Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 276:37402-37408, 2001
31. Silver DL, Jiang XC, Tall AR: Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice: possible role of leptin in stimulation of HDL turnover. J Biol Chem 274:4140-4146, 1999
32. Rohlmann A, Gotthardt M, Hammer RE, Herz J: Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 101:689 -695, 1998
33. Mahley RW, Ji ZS: Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40:1-16, 1999
34. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, Esko JD: Liver heparan sulfate proteoglycans mediate clearance of trig- lyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 117:153-164, 2007
35. Willnow TE, Sheng Z, Ishibashi S, Herz J: Inhibition ofhepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 264: 1471-1474, 1994
36. Cooper AD: Hepatic uptake ofchylomicron remnants. JLipid Res 38:21732192, 1997
37. Out R, Kruijt JK, Rensen PC, Hildebrand RB, de Vos P, Van Eck M, Van Berkel TJ: Scavenger receptor BI plays a role in facilitating chylomicron metabolism. J Biol Chem 279:18401-18406, 2004
38. Kjellen L, Bielefeld D, Hook M: Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 32:337-342, 1983
39. Vogl-Willis CA, Edwards IJ: High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothe- lial cells. Biochim Biophys Acta 1672:36-45, 2004
40. Goldberg IJ: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 86:965-971, 2001
41. Ginsberg HN: Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 14:839 -855, 1991
42. Chait A, Bierman EL, Albers JJ: Low-density lipoprotein receptor activity in cultured human skin fibroblasts: mechanism of insulin-induced stimulation. J Clin Invest 64:1309-1319, 1979
43. Lewis GF, Naples M, Uffelman K, Leung N, Szeto L, Adeli K: Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: studies in insulin-resistant and insulin- sensitized Syrian golden hamsters. Endocrinology 145:5006-5012, 2004
44. Syvanne M, Hilden H, Taskinen MR: Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res 35:15-26, 1994